The purpose of this study was to develop a regimen of docetaxel, cyclophosphamide (CY) and filgrastim for mobilization of peripheral blood stem cells ( The role of HDC with PBSC support for the treatment of patients with breast cancer is controversial 1 despite the fact that numerous phase 2 studies 2-5 and one prospective randomized trial 6 have demonstrated superiority compared to conventional-dose therapies. Patients in complete remission (CR) appear to benefit more from HDC than patients not in CR. 4 Thus, one approach to improving outcomes for patients with metastatic breast cancer is to improve the CR rate prior to HDC with PBSC support.
The role of HDC with PBSC support for the treatment of patients with breast cancer is controversial 1 despite the fact that numerous phase 2 studies [2] [3] [4] [5] and one prospective randomized trial 6 have demonstrated superiority compared to conventional-dose therapies. Patients in complete remission (CR) appear to benefit more from HDC than patients not in CR. 4 Thus, one approach to improving outcomes for patients with metastatic breast cancer is to improve the CR rate prior to HDC with PBSC support.
Theoretically, chemotherapy administered for mobilization of PBSC can be integrated into the treatment plan of patients scheduled to receive HDC. Previous studies in patients with metastatic breast cancer have evaluated induction followed by drug combinations including: cyclophosphamide (CY), etoposide, 7 CY, etoposide and cisplatin 5 and CY and paclitaxel for mobilization of PBSC. 8 The taxanes, paclitaxel and docetaxel, are active in the treatment of patients who have failed doxorubicin-based regimens and are increasingly being evaluated in initial treatment regimens. [9] [10] [11] [12] [13] [14] [15] [16] [17] The administration of paclitaxel or docetaxel prior to HDC with PBSC support is also being evaluated in patients with breast cancer. 18, 19 In order to incorporate new chemotherapeutic agents into a treatment strategy of induction, mobilization of PBSC and HDC with PBSC support it is important to determine the efficacy of such agents for the mobilization of PBSC. The combination of paclitaxel 200 mg/m 2 , CY 3 g/m 2 and filgrastim can be administered with acceptable toxicity allowing collection of adequate quantities of PBSC from the majority of patients with breast cancer. 8, [20] [21] [22] The purpose of the current study was to determine if regimens of docetaxel and CY were also effective for mobilization of PBSC in patients with metastatic breast cancer and to determine if CY 3 g/m 2 could be administered safely with docetaxel 100 mg/m 2 without mesna.
Patients and methods
Between January 1997 and February 1998, 66 patients with metastatic breast cancer meeting protocol eligibility criteria for treatment with HDC were given docetaxel, CY and filgrastim for mobilization of PBSC. Patients were eligible for PBSC mobilization and harvest if they had ECOG performance status of 0-2, age Ͻ66 years, and evidence of adequate hepatic, renal and cardiac function. 23 All patients signed a protocol-specific informed consent approved by the institutional review board of the hospital where the therapy was administered.
Study design
This trial evaluated the toxicities of CY 2, 3 or 4 g/m 2 when combined with docetaxel 100 mg/m 2 . If no dose-limiting toxicities (DLT) were experienced at the three dose levels of CY a randomized trial of CY 3 vs 4 g/m 2 was to be performed evaluating toxicities and CD34 ϩ cell yields. Additional patients were entered at the 2 g/m 2 dose level if patients at the higher dose levels were still being evaluated for toxicity. 
Treatment centers

Administration of chemotherapy and filgrastim
Sixty-six patients received docetaxel (Rhône-Poulenc Rorer, Collegeville, PA, USA) 100 mg/m 2 and CY 2 (n = 10), 3 (n = 27) or 4 g/m 2 (n = 29). Dexamethasone 8 mg p.o. was given twice a day on day 1, docetaxel 100 mg/m 2 was administered i.v. on day 2 and CY 2, 3 or 4 g/m 2 was administered i.v. on day 3. Docetaxel was diluted in 250-500 ml of normal saline in a glass or polyolefin container and infused over 1 h. Cyclophosphamide was diluted in 500 ml of normal saline and infused over 2-3 h. Patients receiving CY 4 g/m 2 received uroprotection with mesna, administered as a 600 mg/m 2 bolus immediately before and after CY and for 24 h as a continuous infusion of 24 mg/m 2 or as two fractionated doses over a 24-h period. Mesna was not administered at the two lower dose levels of CY. Filgrastim (Amgen, Thousand Oaks, CA, USA), 6 g/kg/day, was administered subcutaneously from the day after the end of chemotherapy until completion of apheresis.
Collection and cryopreservation of PBSC
Following the administration of docetaxel, CY and filgrastim PBSC were collected and cryopreserved as previously described. 8, 23 Measurement of CD34 ϩ cells and supportive care procedures have also been previously described. 24, 25 Toxicity grading All patients were evaluated daily until resolution of signs and symptoms and graded for toxicity using standard criteria. 26 A DLT was defined as unresolved grade 4 non-hematologic toxicity according to the common toxicity criteria.
Administration of high-dose chemotherapy
Sixty-one patients have been infused with PBSC following the administration of cyclophosphamide, thiotepa and carboplatin (n = 25), 5 busulfan, melphalan and thiotepa (n = 26) 27 or other HDC regimens (n = 10).
Statistics
All data were collected using a custom designed distributed data system, reviewed at a central clinical trials center (ROI) and analyzed using the SAS system (SAS institute, Cary, NC, USA). The number of CD34 ϩ cells collected ϫ10 6 /kg/apheresis was calculated by dividing the total number of CD34 ϩ cells collected per patient by the number of daily PBSC harvests. Continuous variables were anlayzed using the Wilcoxon rank sum test. Differences in proportions between groups were compared using 2 or Fisher exact method where appropriate. Table 1 shows patient characteristics.
Results
Patient characteristics
Protocol compliance
All patients received the protocol doses of docetaxel, CY and filgrastim and underwent apheresis.
Dose escalation of cyclophosphamide
The first four patients of each cohort receiving CY 2, 3 or 4 g/m 2 did not experience DLT. Six additional patients received CY 2 g/m 2 while higher dose levels were being evaluated.
Comparison of 3 vs 4 g/m 2 of cyclophosphamide
Since there were no DLT observed in the phase I study, 48 more patients were randomized between dose level 2, CY 3 g/m 2 (n = 23) and dose level 3, CY 4 g/m 2 (n = 25).
Non-hematologic toxicities:
Grade 3-4 non-hematologic toxicities occurring in Ͼ5% of patients included nausea (6.1%) and hyperglycemia (9.1%). Grade 3-4 nausea occurred in 3.7% receiving CY 3 g/m 2 and in 6.9% receiving CY 4 g/m 2 (P = 1.00). Hyperglycemia occurred in 0% receiving CY 3 g/m 2 and 6.9% receiving CY 4 g/m 2 (P = 0.49). The incidence of grade 1 hematuria was 7.4% for patients receiving CY 3 g/m 2 and 13.8% following 4 g/m 2 (P = 0.67) with no severe episodes of hemorrhagic cystitis occurring at either dose level.
Hematologic toxicities:
Grade 3-4 hematologic toxicities occurring in Ͼ5% of patients included neutropenia (100%), thrombocytopenia (54%) and anemia (27%). The median duration of neutropenia was 5 days (range, 1-8) for patients receiving CY 3 g/m 2 and 5 days (range, 1-8) for patients receiving CY 
Collection of peripheral blood stem cells
The median yield of CD34 ϩ cells for all patients was 11.06 ϫ . Target CD34 ϩ cell doses у2.5 and у5.0 ϫ 10 6 /kg were achieved in 89% and 79% of patients, respectively.
The median number of CD34 ϩ cells ϫ10 6 /kg/apheresis was 1.86 for patients receiving CY 2 g/m 2 compared to 9.93 for patients receiving 4 g/m 2 (p = 0.02). None of the other comparisons in Table 2 was statistically significant.
Univariate analyses with the number of CD34 ϩ cells collected/kg/apheresis as the endpoint are shown in Table 3 . Fifteen patients who had received only one chemo- 
CD34
ϩ cells/kg compared to 73% of 41 patients who had received у2 regimens (P = 0.03). Patients у50 years of age were less likely to harvest у5.0 ϫ 10 6 CD34 ϩ cells/kg (P = 0.05).
Second attempts to mobilize PBSC
Four of seven patients failing to achieve у2.5 ϫ 10 /kg when first and second collections were combined.
Hematopoietic recovery following high-dose chemotherapy
Fifty-nine patients (89%) have received HDC followed by the infusion of PBSC. The median number of CD34 ϩ cells infused was 7.58 ϫ 10 6 /kg (range, 2.03-53.01). The median days to recovery of neutrophils to 0.5 ϫ 10 
Discussion
In this study the toxicities and efficacy of docetaxel, CY and filgrastim for mobilisation of PBSC were evaluated in patients with metastatic breast cancer. The toxicities observed at all three dose levels of CY were minimal. Eighty-nine per cent of 66 patients harvested у2.5 and 79% harvested у5.0 ϫ 10 6 CD34 ϩ cells/kg with a median of two apheresis procedures. The number of CD34 ϩ cells harvested/kg/apheresis was 1.86 ϫ 10 6 patients receiving CY 2 g/m 2 compared to 9.93 for patients receiving CY 4 g/m 2 (P = 0.02) suggesting a dose effect of CY. There were also more CD34 ϩ cells collected following CY 4 g/m 2 than following 3 g/m 2 but these differences were small and not statistically significant.
There were no statistically significant differences in toxicities between patients receiving 3 or 4 g/m 2 of CY although there was a trend toward a lower frequency of hospitalization for the 3 g/m 2 (3.7%) compared to the 4 g/m 2 group (21%) (P = 0.10). For practical purposes it can be concluded that docetaxel 100 mg/m 2 and CY 3 g/m 2 can be administered without mesna with tolerable toxicities with adequate CD34 ϩ cell yields. In a previous study of CY, 3 g/m 2 and paclitaxel 200 mg/m 2 in patients with metastatic breast cancer the median number of CD34 ϩ cells collected/kg/apheresis was 3.66 compared to 7.12 for patients receiving docetaxel 100 mg/m 2 and CY 3 g/m 2 in the current study. 8 Thus, twice as many CD34 ϩ cells/kg/apheresis were collected following docetaxel and CY as following paclitaxel and CY. However, in the previous paclitaxel study 87% of patients yielded у2.5 ϫ 10 6 CD34 ϩ cells/kg and 73% у5.0 ϫ 10 6 CD34 ϩ cells/kg which is similar to that achieved in the current study (89% and 79%, respectively). 8 Only a randomized trial could determine the relative effectiveness of paclitaxel vs docetaxel for mobilization of PBSC.
Patients who had received у2 chemotherapy regimens had fewer CD34 ϩ cells harvested (P = 0.03) and were less likely to harvest у5.0 ϫ 10 6 CD34 ϩ cells/kg (P = 0.03). Patients у50 years of age were less likely to achieve у5.0 ϫ 10 6 CD34 ϩ cells/kg than younger patients. No other factors were predictive of CD34 ϩ cell yields or achievement of target CD34 ϩ cell doses. In addition to chemotherapy and age, prior studies have also identified performance status and prior radiation as adverse risk factors for mobilizing CD34 ϩ cells. 7, 8, 24, [28] [29] [30] [31] [32] In the current study, only three patients had an ECOG performance status Ͼ0 making this an impossible endpoint to evaluate. Prior radiation was not an adverse risk factor in the current study but this could have been due to the relatively small numbers of patients evaluated.
It is evident that PBSC can be harvested after the administration of a variety of chemotherapeutic agents followed by a growth factor. 7, 8, 24, 29, [31] [32] [33] [34] It is not clear, however, that any regimen is more optimal than another and at the present time it would seem prudent to utilize chemotherapeutic agents for mobilization of PBSC that are appropriate for the disease being treated. In that context, the combination of docetaxel 100 mg/m 2 and CY 3 g/m 2 should prove useful for the management of patients with breast cancer receiving HDC.
